Avid Bioservices Inc (CDMO)

[freethemice]

That is exactly why I think the discrepancies didn't have much of an effect, if they did then that implies the "true" control
arm MOS would be less than 5.6 months. From the table of 12 phase III trials you can see that 5.6 months would be
the smallest. The first trial, Shepherd et al 2000, is the trial that established docetaxel as the standard of care (SOC).
In this case I have the docetaxel arm listed as the "control" arm so it can be compared with the later control
arms of docetaxel only. In fact, at the time the trial was done the SOC was nothing but pain medication,
known as best supportive care (BSC), so that was the "control" arm then and adding docetaxel to BSC would
be the treatment arm. With BSC only, patients lived only 4.6 months, so that marks the smallest value for the MOS.
That is why I think the control arm of the second-line NSCLC was affected very little by the discrepancies.